Higher plasma somatomedin A (biological) and C (immunological) levels with sc than with im growth hormone replacement therapy.
In a short-term cross-over study the effect of daily sc human growth hormone was compared with that of thrice weekly im treatment. At the end of each 6-week treatment period the 10 growth hormone deficient children were admitted to hospital for evaluation of diurnal plasma levels of hormones and intermediary metabolites. Somatomedin A as well as C levels were higher in 9 of 10 children after sc than after im growth hormone therapy. This may be the basis for previous observations of improved growth after change to sc treatment.
D000293:Adolescent; D000328:Adult; D001842:Bone and Bones / Q000378:metabolism; D002648:Child; D002940:Circadian Rhythm; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D005260:Female; D006130:Growth Disorders / Q000097:blood / Q000188:drug therapy*; D013006:Growth Hormone / Q000008:administration & dosage* / Q000172:deficiency; D006801:Humans; D007273:Injections, Intramuscular; D007279:Injections, Subcutaneous; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II; D008297:Male; D013002:Somatomedins / Q000097:blood*
D013002:Somatomedins; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II; D013006:Growth Hormone